Research programme: theta defensins - Oryn Therapeutics

Drug Profile

Research programme: theta defensins - Oryn Therapeutics

Alternative Names: ORTD; ORTD-1; Orynotides; OTP-300; OTP-602

Latest Information Update: 07 Jul 2016

Price : $50

At a glance

  • Originator Oryn Therapeutics
  • Class Antibacterials; Antifungals; Antirheumatics; Macrocyclic compounds; Peptide antibiotics; Peptides
  • Mechanism of Action Defensin modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Rheumatoid arthritis
  • Research Autoimmune disorders

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top